Press Release

London, United Kingdom. 13 August 2026.

Reset Health (“Reset”), the experts in personalised management of chronic disease, today announces the appointment of Dr Joanne Hackett to its Board of Directors. 

Joanne is Vice President and Global Head of Health System Services at IQVIA and was previously Chief Commercial Officer at Genomics England, where she built commercial and industry partnerships around one of the world’s most ambitious genomic medicine programmes. A clinical academic, entrepreneur and investor, she brings deep experience in translating scientific innovation and complex health data into scalable models that work inside real healthcare systems.

Joanne will be integral to Reset’s ongoing work to ensure every patient receives the right therapy, at the right dose and time, with treatment adapted to their response. Her experience will further strengthen Reset’s approach to optimising treatments through continuous clinical care, real-world data, behavioural insight and AI to actively manage therapies across their lifecycle, from initiation and adherence through to real-world outcomes. This is already being delivered across multiple settings: pharmaceutical patient support programmes, intensive clinical care within the NHS, and treatment through pharmacy partners in the private market. 

Dr David Wong, Executive Chairman of Reset Health, commented: “Joanne brings a rare combination of experience across health systems, life sciences, data and precision medicine, and I am thrilled to welcome her to the Board. She immediately enhances our capabilities to optimise treatments for both patients and partners and she will be invaluable as we deliver this across a range of clinical conditions.”

Dr Joanne Hackett said: “I am delighted to join the Board of Reset Health at such an exciting stage in the company’s development. I have long been an advocate for personalised precision medicine, and I believe we now have a real opportunity to use data and technology to make that a reality at scale. Reset is bridging an important gap between medical breakthroughs and how therapies are delivered in the real world, combining continuous care with data-driven insight to ensure treatment is optimised for each individual patient.”

ENDS

For media enquiries, contact 5654 & Company:

Matthew Neal (+44 7917 800 011)  

Steven Scott (+44 7904 407 028)

resethealth@5654.co.uk

Notes to Editors

About Reset Health‍

Reset Health (www.resethealth.clinic) is a digital health company delivering end-to-end management of chronic conditions by combining its Reset Technology Platform (RTP), with the latest innovative evidence-based clinical care pathways for each chronic condition it treats. Reset’s integrated care model for metabolic health, Roczen (www.roczen.com), is used in conjunction with new anti-obesity medications, GLP-1s and GIPs, to enhance health outcomes of patients with obesity and associated co-morbidities.

Reset Health provides care across the UK, Europe and Malaysia where its integrated care models are available to millions of patients, working with pharma, governments, employers, insurers, private providers and health systems.